Sulfur Attached Directly To Urea Nitrogen By Nonionic Bonding Patents (Class 514/592)
  • Publication number: 20020013268
    Abstract: The present invention provides methods of treating non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance, the methods comprising the step of administering to a patient having or at risk of having non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K+ ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K+ ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
    Type: Application
    Filed: April 10, 2001
    Publication date: January 31, 2002
    Inventors: David A. Fryburg, Janice C. Parker
  • Patent number: 6313333
    Abstract: The present invention relates to tetra- and penta-nuclear platinum complexes with antitumor activity, to a method for preparing them and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: November 6, 2001
    Assignee: Setanta Therapeutics, Inc.
    Inventors: Giovanni Da Re, Roberto Di Domenico, Silvano Spinelli, Nicholas Farrell
  • Patent number: 6291495
    Abstract: This invention is directed to a novel method and composition for the treatment of diabetes mellitus (Type I, Impaired Glucose Tolerance [“IGT”] and Type II). More specifically, this invention pertains to a novel method of treating diabetes mellitus by incorporating a therapeutic amount of one or more insulin sensitizers along with one or more of an orally ingested insulin, an injected insulin, a sulfonylurea, a biguanide or an alpha-glucosidase inhibitor for the treatment of diabetes mellitus.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: September 18, 2001
    Inventor: Robert B. Rieveley
  • Patent number: 6281240
    Abstract: This invention provides methods of treating secretory diarrhea or cystic fibrosis in a mammal which comprises administering to a mammal in need thereof an effective amount of diarylsulfonylurea. This invention also describes specific diarylsulfonylureas for use in treating secretory diarrhea or cystic fibrosis.
    Type: Grant
    Filed: January 31, 2000
    Date of Patent: August 28, 2001
    Assignee: Eli Lilly and Company
    Inventor: Bruce D Schultz
  • Publication number: 20010016586
    Abstract: The invention relates to the use of a hypolipidemic agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or delay of the progression to overt diabetes, especially type 2, prevention or reduction of microvascular complications (eg, retinopathy, neurophathy, nephropathy), prevention or reduction of excessive cardiovascular morbidity (eg, myocardial infarction, arterial occlusive disease, atherosclerosis and stroke) and cardiovascular mortality, prevention of cancer and reduction of cancer deaths. Additionally, the invention relates to the use of a treatment for diseases and conditions that are associated with IGM, IGT or IFG.
    Type: Application
    Filed: December 6, 2000
    Publication date: August 23, 2001
    Inventors: Christiane Guitard, Beate Muller, Rebecca Emmons
  • Patent number: 6174921
    Abstract: This invention provides certain substituted benzenesulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: January 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: William J Ehlhardt, James E Ray, John E Toth
  • Patent number: 6153632
    Abstract: This invention is directed to a novel method and composition for the treatment of diabetes mellitus (Type I, Impaired Glucose Tolerance ["IGT"]and Type II). More specifically, this invention pertains to a novel method of treating diabetes mellitus by incorporating a therapeutic amount of one or more insulin sensitizers along with one or more of an orally ingested insulin, an injected insulin, a sulfonylurea, a biguanide or an alpha-glucosidase inhibitor for the treatment of diabetes mellitus.
    Type: Grant
    Filed: February 24, 1997
    Date of Patent: November 28, 2000
    Inventor: Robert B. Rieveley
  • Patent number: 6147115
    Abstract: This invention provides certain sulfonamide compounds, formulations, and a method for treating susceptible neoplasms in mammals using certain sulfonamide compounds.
    Type: Grant
    Filed: March 24, 1993
    Date of Patent: November 14, 2000
    Assignee: Eli Lilly and Company
    Inventors: Thomas A. Crowell, J. Jeffry Howbert, John S. Ward
  • Patent number: 6103761
    Abstract: The invention concerns a series of novel bis-urea derivatives, nonpeptides, which show good binding affinity for the CCK-B receptor. The compounds, compositions containing them, methods of preparation, and utilities including anxiety, gastric acid secretion inhibition, and psychoses are included.
    Type: Grant
    Filed: October 19, 1994
    Date of Patent: August 15, 2000
    Assignee: Warner-Lambert Company
    Inventors: Bradley Dean Tait, Michael William Wilson
  • Patent number: 6071910
    Abstract: A therapeutic method comprising counteracting or preventing pathologies mediated by IL-5, including those characterized by eosinophil infiltration, degranulation and inflammation, by administering to a mammal in need of such therapy, one or more compounds that bind to the eosinophil sulfonylurea receptor, optionally in combination with one or more topical anesthetics and/or glucocorticoids.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: June 6, 2000
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Gerald J. Gleich, Jennifer L. Bankers-Fulbright
  • Patent number: 6043284
    Abstract: The present invention is concerned with diaryl compounds of formula (I) and their use in medical therapy, particularly in the prophylaxis or treatment of a clinical condition for which an ACAT inhibitor is indicated, such as hyperlipidaema or atherosclerosis. The invention also relates to pharmaceutical compositions and processes for the preparation of compounds according to the invention.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: March 28, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: Richard James Arrowsmith, John Gordon Dann, Karl Witold Franzmann, Simon Teanby Hodgson, Peter John Wates
  • Patent number: 5981595
    Abstract: A pharmaceutically useful compound which lowers blood cholesterol levels having the formula ##STR1## wherein X is oxygen or --NH--; Ar is phenyl, substituted phenyl, naphthyl or substituted naphthyl; R.sub.1 is hydrogen, lower alkyl or benzyl; and R.sub.2 is a straight or branched alkyl group having from 5 to 17 carbon atoms which may be substituted on the 1-carbon position with methyl, ethyl, phenyl, or substituted phenyl, or a cycloalkyl group having from 3 to 8 carbon atoms.
    Type: Grant
    Filed: July 1, 1993
    Date of Patent: November 9, 1999
    Assignee: Warner-Lambert Company
    Inventors: Joseph Armand Picard, William Howard Roark, Bruce David Roth
  • Patent number: 5977177
    Abstract: This invention relates to substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them.Substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## exhibit effects on the cardiovascular system.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: November 2, 1999
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinrich Englert, Uwe Gerlach, Dieter Mania, Heinz Gogelein, Joachim Kaiser
  • Patent number: 5972973
    Abstract: Combinations of a sulfonylurea antidiabetic agent and a glitazone antidiabetic agent are useful for treating diabetes mellitus and improving glycemic control.
    Type: Grant
    Filed: October 16, 1998
    Date of Patent: October 26, 1999
    Assignee: Warner-Lambert Company
    Inventor: Randall Wayne Whitcomb
  • Patent number: 5965620
    Abstract: ATP-sensitive K.sup.+ channel modulating compounds are incorporated into ophthalmically acceptable carriers for administration to the eye in order to affect intraocular pressure. Such formulations including compounds which inhibit the channel are particularly suitable for treating glaucoma and other disorders related to elevated intraocular pressure. Such formulation which potentiates the channel are particularly suitable for treating hypotonia and other depressed intraocular pressure conditions.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: October 12, 1999
    Assignee: Vide Pharmaceuticals
    Inventors: Nino Sorgente, Charles Bakhit
  • Patent number: 5880155
    Abstract: This invention relates to substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them.Substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## exhibit effects on the cardiovascular system.
    Type: Grant
    Filed: February 15, 1996
    Date of Patent: March 9, 1999
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinrich Englert, Uwe Gerlach, Dieter Mania, Heinz Gogelein, Joachim Kaiser
  • Patent number: 5776980
    Abstract: Benzenesulfonylureas and -thioureas of the formula I ##STR1## where R(1) is H or (fluoro)methyl, R(2) is H, Hal or (fluoro)(mercapto)alk(oxy)yl, E is O or S; Y is --?CR(3).sub.2 !.sub.n --, where R(3)=H or alkyl and n=1-4, X is H, Hal or alkyl and Z is Hal, NO.sub.2 or alk(yl)oxy, are described.The compounds I are used for treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrhythmia, and can therefore be used as antiarrhythmics. They are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.
    Type: Grant
    Filed: November 7, 1996
    Date of Patent: July 7, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinrich Englert, Dieter Mania, Jens Hartung, Heinz Gogelein, Joachim Kaiser, Wolfgang Linz, David Wettlaufer
  • Patent number: 5719192
    Abstract: A method of use comprising administering terbinafine for the primary and secondary prophylaxis and treatment of Pneumocystis carinii pneumonia, including oral administration of terbinafine at does of 3 to 20 mg/kg/day, to a subject suffering from this type of pneumonia is disclosed.
    Type: Grant
    Filed: September 12, 1995
    Date of Patent: February 17, 1998
    Assignee: Mendes s.r.l.
    Inventors: Claudio De Simone, Carlo Contini, Sonia Tzoutzoglou
  • Patent number: 5698596
    Abstract: Substituted benzenesulfonylureas and -thioureas--processes for their preparation and their use as pharmaceuticalsBenzenesulfonylureas and -thioureas of the formula I ##STR1## where R(1) is H or (fluoro)methyl, R(2) is H, Hal or (fluoro)(mercapto)alk(oxy)yl, E is O or S; Y is --?CR(3).sub.2 !.sub.n --, where R(3)=H or alkyl and n=1-4, X is H, Hal or alkyl and Z is Hal, NO.sub.2 or alk(yl)oxy, are described.The compounds I are used for treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrhythmia, and can therefore be used as antiarrhythmics. They are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.
    Type: Grant
    Filed: September 3, 1996
    Date of Patent: December 16, 1997
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinrich Englert, Dieter Mania, Jens Hartung, Heinz Gogelein, Joachim Kaiser, Wolfgang Linz, David Wettlaufer
  • Patent number: 5677344
    Abstract: A method is provided for treatment of Parkinson's disease or controlling movement of a Parkinsonian patient by administering an ATP-sensitive potassium channel blocker, such as a sulfonyl urea, (for example, tolbutamide), or quinine.
    Type: Grant
    Filed: May 24, 1993
    Date of Patent: October 14, 1997
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Susan A. Greenfield, Denyse Levesque
  • Patent number: 5652268
    Abstract: This invention relates to substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use as a medicament or diagnostic, and medicament containing them.Substituted benzenesulfonylureas and -thioureas 1 ##STR1## exhibit effects on the cardiovascular system.
    Type: Grant
    Filed: February 15, 1996
    Date of Patent: July 29, 1997
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinrich Englert, Uwe Gerlach, Dieter Mania, Heinz Gogelein, Joachim Kaiser
  • Patent number: 5643853
    Abstract: Thiol compounds are employed in conjunction with compounds which modulate self proliferation, both as to plants and mammals. The thiol compounds find effect in enhancing the effectiveness of auxin like compounds, either as herbicides or in enhancing root formation. In addition, thiol compounds act in conjunction with cytotoxic agents in mammals to allow for lower dosages of the cytotoxic agents while retaining the cytotoxic effect against hyperproliferative diseases, such as cancer. The combination finds particular effect against cells dependent upon an isoform of a surface membrane NADH oxidase for proliferation.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: July 1, 1997
    Assignee: Purdue Research Foundation
    Inventor: D. James Morre
  • Patent number: 5629345
    Abstract: ATP-sensitive K.sup.+ channel modulating compounds are incorporated into ophthalmically acceptable carriers for administration to the eye in order to affect intraocular pressure. Such formulations including compounds which inhibit the channel are particularly suitable for treating glaucoma and other disorders related to elevated intraocular pressure. Such formulation which potentiates the channel are particularly suitable for treating hypotonia and other depressed intraocular pressure conditions.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: May 13, 1997
    Assignee: Vide Pharmaceuticals
    Inventors: Nino Sorgente, Charles Bakhit
  • Patent number: 5594028
    Abstract: This invention provides certain sulfonamide derivatives, their pharmaceutical formulations, and their use in the treatment of susceptible neoplasms in mammals.
    Type: Grant
    Filed: November 21, 1994
    Date of Patent: January 14, 1997
    Assignee: Eli Lilly and Company
    Inventors: Richard W. Harper, J. Jeffry Howbert, Gerald A. Poore, Brent J. Rieder, Eddie V. P. Tao, James A. Aikins
  • Patent number: 5574069
    Abstract: Benzenesulfonylureas and -thioureas of the formula I ##STR1## where R(1) is H or (fluoro)methyl, R(2) is H, Hal or (fluoro) (mercapto) alk (oxy) yl, E is O or S; Y is --[CR(3).sub.2 ]n-, where R(3)=H or alkyl and n=1-4, X is H, Hal or alkyl and Z is Hal, NO.sub.2 or alk(yl)oxy, are described.The compounds I are used for treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrhythmia, and can therefore be used as antiarrhythmics. They are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: November 12, 1996
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinrich Englert, Dieter Mania, Jens Hartung, Heinz Gogelein, Joachim Kaiser, Wolfgang Linz, David Wettlaufer
  • Patent number: 5565494
    Abstract: This invention provides certain benzenesulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier, and processes for preparing the benzenesulfonamide derivatives.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: October 15, 1996
    Assignee: Eli Lilly and Company
    Inventors: Gerald B. Grindey, Cora S. Grossman, J. Jeffry Howbert, Karen L. Lobb, James E. Ray, John E. Toth
  • Patent number: 5476850
    Abstract: There are described amino-substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## The compounds I are used for the treatment of cardiac arrhythmias and for the prevention of sudden heart death caused by arrhythmias and can therefore be used as antiarrhythmics. They are particularly suitable for those cases in which arrhythmias are a result of constriction of a coronary vessel, such as in angina pectoris or in acute cardiac infarct.
    Type: Grant
    Filed: December 5, 1994
    Date of Patent: December 19, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinrich Englert, Dieter Mania, Jens Hartung, Heinz Gogelein, Joachim Kaiser
  • Patent number: 5451580
    Abstract: A method is provided for treatment of neuronal insult, such as caused by lack of oxygen, which neurons are prone to Parkinsonian degeneration by administering an ATP-sensitive potassium channel blocker, such as a sulfonyl urea, for example, tolbutamide.
    Type: Grant
    Filed: September 22, 1993
    Date of Patent: September 19, 1995
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Kerry P. S. J. Murphy, Susan A. Greenfield
  • Patent number: 5389682
    Abstract: The invention concerns a series of novel bis-urea derivatives, nonpeptides, which show good binding affinity for the CCK-B receptor. The compounds, compositions containing them, methods of preparation, and utilities including anxiety, gastric acid secretion inhibition, and psychoses are included.
    Type: Grant
    Filed: September 13, 1993
    Date of Patent: February 14, 1995
    Assignee: Warner-Lambert Company
    Inventors: Bradley D. Tait, Michael W. Wilson
  • Patent number: 5364850
    Abstract: The present invention provides substituted tyrosyl diamide compounds of general Formula I: ##STR1## and the pharmaceutically-acceptable salts thereof, which are useful for inducing analgesia in animals, pharmaceutical compositions comprising a pharmaceutically-acceptable carrier and a compound of Formula I, and a method for inducing analgesia in an animal in need thereof comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.
    Type: Grant
    Filed: September 24, 1993
    Date of Patent: November 15, 1994
    Assignee: G. D. Searle & Co.
    Inventors: Donald W. Hansen, Jr., Nizal S. Chandrakumar, Karen B. Peterson, Sofya Tsymbalov, Robert K. Husa
  • Patent number: 5354778
    Abstract: This invention provides certain N-phenyl-N'-substituted phenylsulfonylureas compounds, formulations, and a method for treating susceptible neoplasms in mammals using the sulfonylurea compounds.
    Type: Grant
    Filed: March 26, 1993
    Date of Patent: October 11, 1994
    Assignee: Eli Lilly and Company
    Inventors: James E. Ray, John E. Toth, J. Jeffry Howbert
  • Patent number: 5304575
    Abstract: Bezafibrate is used for the treatment of normolipidaemic diabetes mellitus type II.
    Type: Grant
    Filed: December 17, 1992
    Date of Patent: April 19, 1994
    Assignee: Boehringer Mannheim GmbH
    Inventor: Walter Beck
  • Patent number: 5272175
    Abstract: The present invention provides substituted tyrosyl diamide compounds of general Formula I: ##STR1## and the pharmaceutically-acceptable salts thereof, which are useful for inducing analgesia in animals, pharmaceutical compositions comprising a pharmaceutically-acceptable carrier and a compound of Formula I, and a method for inducing analgesia in an animal in need thereof comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.
    Type: Grant
    Filed: May 20, 1992
    Date of Patent: December 21, 1993
    Assignee: G. D. Searle & Co.
    Inventors: Donald W. Hansen, Jr., Nizal S. Chandrakumar, Karen B. Peterson, Sofya Tsymbalov, Robert K. Husa
  • Patent number: 5260338
    Abstract: This invention provides the use of certain benzenesulfonamide derivatives in the treatment of susceptible neoplasms in mammals. Also provided are certain novel benzenesulfonamide derivatives and their pharmaceutical formulations.
    Type: Grant
    Filed: January 28, 1992
    Date of Patent: November 9, 1993
    Assignee: Eli Lilly and Company
    Inventors: Richard W. Harper, Gerald A. Poore, Brent J. Rieder
  • Patent number: 5254589
    Abstract: A pharmaceutically useful compound which lowers blood cholesterol levels having the formula ##STR1## wherein X is oxygen or --NH--; Ar is phenyl, substituted phenyl, naphthyl or substituted naphthyl; R.sub.1 is hydrogen, lower alkyl or benzyl; and R.sub.2 is a straight or branched alkyl group having from 5 to 17 carbon atoms which may be substituted on the 1-carbon position with methyl, ethyl, phenyl, or substituted phenyl, or a cycloalkyl group having from 3 to 8 carbon atoms.
    Type: Grant
    Filed: October 15, 1991
    Date of Patent: October 19, 1993
    Assignee: Warner-Lambert Company
    Inventors: Joseph A. Picard, William H. Roark, Bruce D. Roth
  • Patent number: 5234922
    Abstract: Methods for the treatment of secretory diarrhea comprised of administering to a patient in need thereof, an effective amount of a CFTR chloride channel blocker or a potassium channel opener are disclosed. The CFTR chloride channel blocker is a sulfonylurea of the group consisting of tolbutamide, glibenclamide, and related analogs. The potassium channel opener is selected from the group consisting of diazoxide, lemakalim, and minoxidil sulfate.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: August 10, 1993
    Assignee: University of Iowa Research Foundation
    Inventors: Michael J. Welsh, David N. Sheppard
  • Patent number: 5234955
    Abstract: This invention provides certain N-phenyl-N'-substitutedphenylsulfonylureas compounds, formulations, and a method for treating susceptible neoplasms in mammals using the sulfonylurea compounds.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: August 10, 1993
    Assignee: Eli Lilly and Company
    Inventors: James E. Ray, John E. Toth, J. Jeffry Howbert
  • Patent number: 5216026
    Abstract: A method is provided for treating a susceptible neoplasm in mammals which comprises administering to a mammal in need of said treatment an effective amount for treating the neoplasm of the compound N-[[(4-chlorophenyl)amino]carbonyl]-1-butanesulfonamide or a pharmaceutically acceptable salt thereof, wherein said neoplasm is selected from the group consisting of ovarian, non-small cell lung, gastric, pancreatic, renal cell, breast, colorectal, small-cell lung, melanoma, head and neck, Kaposi's sarcoma, and rhabdomyosarcoma.
    Type: Grant
    Filed: July 17, 1990
    Date of Patent: June 1, 1993
    Assignee: Eli Lilly and Company
    Inventor: J. Jeffry Howbert
  • Patent number: 5215985
    Abstract: A method is provided for treatment of neuronal insult, such as caused by lack of oxygen, by administering an ATP-sensitive potassium channel blocker, such as a sulfonyl urea, for example, tolbutamide.
    Type: Grant
    Filed: January 27, 1992
    Date of Patent: June 1, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Kerry P. S. J. Murphy, Susan A. Greenfield
  • Patent number: 5116874
    Abstract: This invention provides certain N-[(phenyl)amino]carbonyl-bicyclicsulfonamide sulfonamide derivatives, their pharmaceutical formulations, and their use in the treatment of susceptible neoplasms in mammals.
    Type: Grant
    Filed: May 15, 1989
    Date of Patent: May 26, 1992
    Assignee: Eli Lilly and Company
    Inventor: Gerald A. Poore
  • Patent number: 5110830
    Abstract: This invention provides the use of certain benzenesulfonamide derivatives in the treatment of susceptible neoplasms in mammals. Also provided are certain novel benzenesulfonamide derivatives and their pharmaceutical formulations.
    Type: Grant
    Filed: September 13, 1990
    Date of Patent: May 5, 1992
    Assignee: Eli Lilly and Company
    Inventors: Richard W. Harper, Gerald A. Poore, Brent J. Rieder
  • Patent number: 5091180
    Abstract: The present invention is directed to the in vivo use of compounds which prevent the generation of, effectively scavenge, or detoxify a reactive oxygen metabolite that mediates a toxic effect of rhabdomyolysis and myoglobinuria. The compounds of the invention can be used to prevent or reduce rhabdomyolysis-induced renal damage, and include but are not limited to free radical scavengers, iron chelators, oxidizable compounds, enzymes which metabolize reactive oxygen metabolites or their precursors, and biosynthetic precursors thereof.
    Type: Grant
    Filed: November 30, 1990
    Date of Patent: February 25, 1992
    Assignee: Administrators of the Tulane Educational Fund
    Inventors: Patrick D. Walker, Sudhir V. Shah
  • Patent number: 5047429
    Abstract: A method is described for treating and/or preventing pulmonary oedema in patients comprising administering a suphonylurea compound or a pharmaceutically acceptable salt thereof to patients who suffer from or are susceptible to oedema. Glucose may also be simultaneously administered to the patients to prevent hypoglycemia.
    Type: Grant
    Filed: April 18, 1989
    Date of Patent: September 10, 1991
    Assignee: Hoechst Aktiengesellschaft
    Inventor: Piers C. G. Nye
  • Patent number: 4845128
    Abstract: This invention provides the use of certain benzenesulfonamide derivatives in the treatment of susceptible neoplasms in mammals. Also provided are certain novel benzenesulfonamide derivatives and their pharmaceutical formulations.
    Type: Grant
    Filed: May 2, 1985
    Date of Patent: July 4, 1989
    Assignee: Eli Lilly and Company
    Inventors: Richard W. Harper, Gerald A. Poore, Brent J. Rieder
  • Patent number: 4701457
    Abstract: Amidinoureas are disclosed as useful for the treatment of irritable bowel syndrome.
    Type: Grant
    Filed: January 13, 1984
    Date of Patent: October 20, 1987
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: John Yelnosky, Ghulam N. Mir
  • Patent number: 4698365
    Abstract: Compounds of the formula ##STR1## in which "halogen" represents chlorine or fluorine and n is zero, one, two or three, that have useful pesticidal activity.
    Type: Grant
    Filed: November 25, 1986
    Date of Patent: October 6, 1987
    Assignee: E. I. Du Pont de Nemours and Company
    Inventor: Martin Anderson
  • Patent number: 4515812
    Abstract: N-Sulphenylated ureas of the formula ##STR1## in which R.sup.1 to R.sup.6 each independently is hydrogen, halogen, nitro, cyano, alkyl, alkoxy, alkylmercapto, trihalogenomethyl-, trihalogenomethoxy or trihalogenomethylmercapto,R.sup.7 is hydrogen or alkyl, andn is 0, 1, 2 or 3,which possess fungicidal properties.
    Type: Grant
    Filed: April 4, 1983
    Date of Patent: May 7, 1985
    Assignee: Bayer Aktiengesellschaft
    Inventors: Engelbert Kuhle, Wilhelm Brandes, Paul-Ernst Frohberger
  • Patent number: 4497822
    Abstract: Insecticidally active benzoylphenylurea derivatives of the formula: ##STR1## wherein R is haloalkyl, or phenyl optionally substituted by certain substituents and the other symbols have assigned meanings.
    Type: Grant
    Filed: April 14, 1983
    Date of Patent: February 5, 1985
    Assignee: Shell Oil Company
    Inventor: Martin Anderson